- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05208047
(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
En fase 3 randomisert, åpen, multisenter klinisk studie av CGT9486+Sunitinib vs. Sunitinib hos personer med lokalt avanserte, uoperable eller metastatiske gastrointestinale stromale svulster
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Cogent Biosciences
- Telefonnummer: 617-945-5576
- E-post: peakinfo@cogentbio.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Aktiv, ikke rekrutterende
- Instituto Alexander Fleming
-
Córdoba, Argentina, X5000HWE
- Aktiv, ikke rekrutterende
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Bankstown, Australia, 2200
- Aktiv, ikke rekrutterende
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Aktiv, ikke rekrutterende
- Sir Charles Gairdner Hospital
-
-
-
-
-
Campinas, Brasil, 130.83-888
- Aktiv, ikke rekrutterende
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro, Brasil, 20.230-130
- Aktiv, ikke rekrutterende
- lnstituto Nacional de Cancer - INCA
-
São Paulo, Brasil, 09060-650
- Aktiv, ikke rekrutterende
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Calgary, Canada, T2N 4N2
- Rekruttering
- Tom Baker Cancer Center
-
Montreal, Canada, HIT 2M4
- Aktiv, ikke rekrutterende
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Rekruttering
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Hospital
-
-
-
-
-
Santiago, Chile, 7500921
- Aktiv, ikke rekrutterende
- Instituto Oncologico FALP
-
Santiago, Chile, 7560908
- Aktiv, ikke rekrutterende
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Aarhus, Danmark, 8200
- Aktiv, ikke rekrutterende
- Aarhus University Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35249
- Tilbaketrukket
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85259
- Rekruttering
- Mayo Clinic
-
Tucson, Arizona, Forente stater, 85719
- Aktiv, ikke rekrutterende
- University of Arizona- Cancer Center
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope
-
Los Angeles, California, Forente stater, 90404
- Aktiv, ikke rekrutterende
- University of California, Los Angeles (UCLA)
-
San Diego, California, Forente stater, 92093
- Rekruttering
- University of California, San Diego (UCSD)
-
San Francisco, California, Forente stater, 94158
- Aktiv, ikke rekrutterende
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Forente stater, 80204
- Rekruttering
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Jacksonville
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City, Florida, Forente stater, 32763
- Tilbaketrukket
- Mid Florida Hematology and Oncology Center
-
Orlando, Florida, Forente stater, 32806
- Rekruttering
- Orlando Health Cancer Institute
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Aktiv, ikke rekrutterende
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63130
- Rekruttering
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Rekruttering
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo, New York, Forente stater, 14203
- Aktiv, ikke rekrutterende
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Forente stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Duke University
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, Forente stater, 43614
- Tilbaketrukket
- University of Toledo Medical Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Rekruttering
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Rekruttering
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Rekruttering
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- Tilbaketrukket
- University of Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Forente stater, 77030-4009
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Aktiv, ikke rekrutterende
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53705
- Rekruttering
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Bordeaux, Frankrike, 33076
- Aktiv, ikke rekrutterende
- Institut Bergonie
-
Lille, Frankrike, 59000
- Aktiv, ikke rekrutterende
- Centre Oscar Lambret
-
Lyon, Frankrike, 69008
- Aktiv, ikke rekrutterende
- Centre Leon Berard
-
Marseille, Frankrike, 13005
- Aktiv, ikke rekrutterende
- AP-HM - Hôpital de la Timone
-
Rennes, Frankrike, 35042
- Aktiv, ikke rekrutterende
- Centre Eugene Marquis
-
Saint-Herblain, Frankrike, 44800
- Aktiv, ikke rekrutterende
- ICO St-Herblain
-
Toulouse, Frankrike, 31400
- Aktiv, ikke rekrutterende
- CHU de Toulouse - Hospital Rangueil
-
Villejuif, Frankrike, 94805
- Aktiv, ikke rekrutterende
- Gustave Roussy
-
-
-
-
-
Central, Hong Kong
- Tilbaketrukket
- Humanity & Health Clinical Trial Centre
-
Jordon, Hong Kong
- Aktiv, ikke rekrutterende
- Hong Kong United Oncology Centre
-
Shatin, Hong Kong
- Aktiv, ikke rekrutterende
- Prince of Wales Hospital
-
-
-
-
-
Aviano, Italia, 33081
- Aktiv, ikke rekrutterende
- Centro Riferimento Oncologico - Aviano
-
Bologna, Italia, 40138
- Aktiv, ikke rekrutterende
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia, Italia, 25123
- Aktiv, ikke rekrutterende
- ASST degli Spedali Civili di Brescia
-
Candiolo, Italia, 10060
- Tilbaketrukket
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence, Italia, 50134
- Aktiv, ikke rekrutterende
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola, Italia, 47014
- Aktiv, ikke rekrutterende
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan, Italia, 20133
- Aktiv, ikke rekrutterende
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Italia, 20141
- Aktiv, ikke rekrutterende
- Istituto Europeo di Oncologia
-
Palermo, Italia, 90127
- Aktiv, ikke rekrutterende
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma, Italia, 00128
- Aktiv, ikke rekrutterende
- Policlinico Universitario Campus Bio-Medico
-
Rozzano, Italia, 20089
- Aktiv, ikke rekrutterende
- Istituto Clinico Humanitas
-
Verona, Italia, 31726
- Aktiv, ikke rekrutterende
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Aguascalientes, Mexico, 20116
- Tilbaketrukket
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey, Mexico, 64710
- Aktiv, ikke rekrutterende
- I Can Oncology Center SA De CV
-
Oaxaca City, Mexico, 68000
- Tilbaketrukket
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Amsterdam, Nederland, 1066 CX
- Aktiv, ikke rekrutterende
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen, Nederland, 9713 GZ
- Aktiv, ikke rekrutterende
- UMC Groningen
-
Nijmegen, Nederland, 6525 GA
- Aktiv, ikke rekrutterende
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam, Nederland, 3015 GD
- Aktiv, ikke rekrutterende
- Erasmus MC
-
-
-
-
-
Bergen, Norge, 5021
- Aktiv, ikke rekrutterende
- Haukeland University Hospital - Bergen
-
Oslo, Norge, 0310
- Aktiv, ikke rekrutterende
- Oslo University Hospital
-
-
-
-
-
Brzozów, Polen, 36-200
- Aktiv, ikke rekrutterende
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz, Polen, 85-796
- Tilbaketrukket
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice, Polen, 44-102
- Aktiv, ikke rekrutterende
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw, Polen, 02-781
- Aktiv, ikke rekrutterende
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Barcelona, Spania, 08035
- Aktiv, ikke rekrutterende
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spania, 08041
- Tilbaketrukket
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona, Spania, 08908
- Aktiv, ikke rekrutterende
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar, Spania, 30120
- Tilbaketrukket
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid, Spania, 28041
- Aktiv, ikke rekrutterende
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28040
- Aktiv, ikke rekrutterende
- Hospital Clinico San Carlos
-
Madrid, Spania, 28007
- Aktiv, ikke rekrutterende
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spania, 28040
- Aktiv, ikke rekrutterende
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela, Spania, 15706
- Aktiv, ikke rekrutterende
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville, Spania, 41013
- Aktiv, ikke rekrutterende
- Hospital Universitario Virgen del Rocio
-
Zaragoza, Spania, 50009
- Tilbaketrukket
- Hospital Universitario Miguel Servet
-
-
-
-
-
Cambridge, Storbritannia, CB2 0QQ
- Aktiv, ikke rekrutterende
- Cambridge Addenbrooke's Hospital
-
Glasgow, Storbritannia, G12 0YN
- Tilbaketrukket
- Beatson, West of Scotland Cancer Centre
-
London, Storbritannia, NW1 2PG
- Aktiv, ikke rekrutterende
- University College London Hospital
-
London, Storbritannia, SW3 6JJ
- Aktiv, ikke rekrutterende
- Royal Marsden Hospital - Surrey
-
London, Storbritannia, SE1 9RT
- Tilbaketrukket
- Guy's Hospital
-
Manchester, Storbritannia, M20 4BX
- Aktiv, ikke rekrutterende
- The Christie NHS Foundation Trust
-
Sheffield, Storbritannia, S10 2SJ
- Aktiv, ikke rekrutterende
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Lund, Sverige, 22185
- Aktiv, ikke rekrutterende
- Skane University Hospital Lund
-
Solna, Sverige, 171 76
- Aktiv, ikke rekrutterende
- Karolinska University Hospital
-
-
-
-
-
Seoul, Sør -Korea, 03080
- Aktiv, ikke rekrutterende
- Seoul National University Hospital
-
Seoul, Sør -Korea, 06351
- Aktiv, ikke rekrutterende
- Samsung Medical Center
-
Seoul, Sør -Korea, 08308
- Aktiv, ikke rekrutterende
- Korea University Guro Hospital
-
Seoul, Sør -Korea, 05505
- Aktiv, ikke rekrutterende
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Sør -Korea, 10408
- Tilbaketrukket
- National Cancer Center
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Aktiv, ikke rekrutterende
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City, Taiwan, 10002
- Aktiv, ikke rekrutterende
- National Taiwan University Hospital
-
Taichung, Taiwan, 40447
- Aktiv, ikke rekrutterende
- China Medical University Hospital
-
Taipei, Taiwan, 11217
- Aktiv, ikke rekrutterende
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan, Taiwan, 33305
- Aktiv, ikke rekrutterende
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
-
-
-
Brno, Tsjekkia, 65653
- Aktiv, ikke rekrutterende
- Masarykuv onkologicky ustav
-
Hradec Králové, Tsjekkia, 500 05
- Tilbaketrukket
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tsjekkia, 77900
- Aktiv, ikke rekrutterende
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Bad Saarow, Tyskland, 15526
- Aktiv, ikke rekrutterende
- Helios Klinikum Bad Saarow
-
Berlin, Tyskland, 13125
- Aktiv, ikke rekrutterende
- Helios Klinikum Berlin-Buch
-
Essen, Tyskland, 45147
- Aktiv, ikke rekrutterende
- Universitaetsklinikum Essen
-
Hamburg, Tyskland, 20246
- Aktiv, ikke rekrutterende
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover, Tyskland, 30625
- Aktiv, ikke rekrutterende
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim, Tyskland, 68167
- Aktiv, ikke rekrutterende
- Universitaetsmedizin Mannheim
-
-
-
-
-
Debrecen, Ungarn, 4032
- Aktiv, ikke rekrutterende
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Eksperimentell: Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Aktiv komparator: Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Eksperimentell: Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Eksperimentell: Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Eksperimentell: DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
Eksperimentell: GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Andre navn:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Andre navn:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
Tidsramme: 16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
Tidsramme: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
Tidsramme: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
Tidsramme: 14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
Tidsramme: 14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
Tidsramme: Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
Tidsramme: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
Tidsramme: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
Tidsramme: Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Tidsramme: Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Tidsramme: Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Tidsramme: Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
Tidsramme: Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
Tidsramme: Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
Tidsramme: Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
Tidsramme: Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
Tidsramme: Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Tidsramme: Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer
- Neoplasmer etter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Neoplastiske prosesser
- Neoplasmer, bindevev og mykt vev
- Neoplasmer, bindevev
- Patologiske tilstander, tegn og symptomer
- Neoplasma Metastase
- Gastrointestinale stromale svulster
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Azoler
- Indoler
- Benzazepiner
- Pyrroles
- Benzodiazepiner
- Sunitinib
- Midazolam
Andre studie-ID-numre
- CGT9486-21-301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .